BORA PHARMACEUTICALS LTD Cash Flow Quality Index
BORA PHARMACEUTICALS LTD cash flow quality index. BORA PHARMACEUTICALS LTD (6472) has a Cash Flow Quality Index of 14.11x as of March 2026. Operating cash flow of NT$568.46 Million exceeds net income of NT$40.29 Million, indicating high earnings quality where cash backs reported profits. See 6472 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BORA PHARMACEUTICALS LTD (2019–2025)
Cash flow quality index of BORA PHARMACEUTICALS LTD from 2019 to 2025. Historical Cash Flow Quality Index for BORA PHARMACEUTICALS LTD across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore how well can BORA PHARMACEUTICALS LTD service its debt to assess how comfortably operating cash covers total debt obligations.
BORA PHARMACEUTICALS LTD Cash Flow Quality Index by Year (2019–2025)
BORA PHARMACEUTICALS LTD cash flow quality index by year from 2019 to 2025. Year-by-year earnings quality comparison for BORA PHARMACEUTICALS LTD. For the full cash flow conversion analysis, see 6472 cash generation efficiency.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.42x | NT$4.24 Billion | NT$2.98 Billion | ▲ +618.8% |
| 2024 | 0.20x | NT$980.81 Million | NT$4.95 Billion | ▼ -82.6% |
| 2023 | 1.14x | NT$4.61 Billion | NT$4.06 Billion | ▲ +3.9% |
| 2022 | 1.09x | NT$2.01 Billion | NT$1.84 Billion | ▼ -9.5% |
| 2021 | 1.21x | NT$1.24 Billion | NT$1.02 Billion | ▲ +304.4% |
| 2020 | 0.30x | NT$177.79 Million | NT$595.40 Million | ▼ -60.7% |
| 2019 | 0.76x | NT$231.77 Million | NT$305.03 Million | — |